Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Song, Bo ^a   Wang, Yuan ^a,b   Titmus, Matthew A ^a   Botchkina, Galina ^a   Formentini, Andrea ^c   Kornmann, Marko ^c   Ju, Jingfang ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; DENTICLELESS PROTEIN HOMOLOG; DIHYDROFOLATE REDUCTASE; HERMES ANTIGEN; METHOTREXATE; MICRORNA; MICRORNA 215; PROTEIN P21; PROTEIN P53; RALTITREXED; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DTL PROTEIN, HUMAN; NUCLEAR PROTEIN; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; UPREGULATION; ADULT; AGED; BIOSYNTHESIS; COLON TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; MIDDLE AGED; OSTEOSARCOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; METHOTREXATE; MICRORNAS; MIDDLE AGED; NUCLEAR PROTEINS; OSTEOSARCOMA; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TETRAHYDROFOLATE DEHYDROGENASE; THIOPHENES; THYMIDYLATE SYNTHASE; TRANSFECTION;

EID: 77951597361     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-96     Document Type: Article

References (52)

1. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002, 1587:164-173.
2. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995, 64:721-762. 10.1146/annurev.bi.64.070195.003445, 7574499.
3. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6:1322-1327.
4. Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch Surg 2004, 389:405-413. 10.1007/s00423-004-0510-y, 15309542.
5. Johnston PG, Benson AB, Catalano P, Rao MS, O'Dwyer PJ, Allegra CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 2003, 21:815-819. 10.1200/JCO.2003.07.039, 12610179.
6. Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 2007, 59:839-845. 10.1007/s00280-006-0384-5, 17119966.
7. Sheikh MS, Fornace AJ. Regulation of translation initiation following stress. Oncogene 1999, 18:6121-6128. 10.1038/sj.onc.1203131, 10557103.
8. Chu E, Copur S, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF, Maley F, Allegra CJ. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol 1999, 19:1582-1594. 116086, 9891091.
9. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 1999, 96:3769-3774. 10.1073/pnas.96.7.3769, 22369, 10097112.
10. Ju J, Huang C, Minskoff S, Mayotte J, Taillon B, Simons JF. Simultaneous gene expression analysis of steady-state and actively translated mRNA populations from osteosarcoma MG-63 cells in response to IL-1α via an open expression analysis platform. Nucleic Acids Res 2003, 31:5157-5166. 10.1093/nar/gkg702, 212802, 12930967.
11. Fu L, Minden MD, Benchimol S. Translational regulation of human p53 gene expression. EMBO J 1996, 15:4392-4401. 452163, 8861966.
12. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991, 88:8977-8981. 10.1073/pnas.88.20.8977, 52634, 1924359.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854. 10.1016/0092-8674(93)90529-Y, 8252621.
14. Kozak M. Faulty old ideas about translational regulation paved the way for current confusion about how microRNAs function. Gene 2008, 423:108-115. 10.1016/j.gene.2008.07.013, 18692553.
15. Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene 2006, 25:6163-6169. 10.1038/sj.onc.1209909, 17028595.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
17. Lewis BP, Burge C, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20. 10.1016/j.cell.2004.12.035, 15652477.
18. Verghese ET, Hanby A, Speirs V, Hughes TA. Small is beautiful: microRNAs and breast cancer-where are we now?. J Pathol 2008, 215:214-221. 10.1002/path.2359, 18446835.
19. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006, 12:2014-2024. 10.1158/1078-0432.CCR-05-1853, 16609010.
20. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134. 10.1038/nature05939, 17554337.
21. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007, 67:11099-11101. 10.1158/0008-5472.CAN-07-2672, 18056431.
22. Xi Y, Edwards JR, Ju J. Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer-regulatory relationship of c-Myc and p53 with miRNAs. Cancer Inform 2007, 3:245-253. 2133370,2133370, 18079974.
23. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
24. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell Biol 2007, 26:731-743.
25. Song B, Wang Y, Kudo K, Gavin E, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res 2008, 14:8080-8086. 10.1158/1078-0432.CCR-08-1422, 2653201, 19088023.
26. Pan HW, Chou HY, Liu SH, Peng SY, Liu CL, Hsu HC. Role of L2DTL, cell cycle-regulated nuclear and centrosome protein, in aggressive hepatocellular carcinoma. Cell Cycle 2006, 5:2676-2687.
27. Ueki L, Nishidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene 2008, 27:5672-5683. 10.1038/onc.2008.186, 18542055.
28. Li J, Ng EK, Ng YP, Wong CY, Yu J, Jin H, Cheng VY, Go MY, Cheung PK, Ebert MP, Tong J, To KF, Chan FK, Sung JJ, Ip NY, Leung WK. Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer. Br J Cancer 2009, 101:691-698. 10.1038/sj.bjc.6605202, 19672268.
29. Zou GM. Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol 2008, 217:598-604. 10.1002/jcp.21541, 18651561.
30. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 2004, 64:1431-1435. 10.1158/0008-5472.CAN-03-1203, 14973067.
31. Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?. Cancer Biol Ther 2008, 7:986-994.
32. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, Jackson AL, Carleton MO, Linsley PS, Cleary MA, Chau BN. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res 2008, 68:10105-10112. 10.1158/0008-5472.CAN-08-1846, 19074876.
33. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-2129. 10.1053/j.gastro.2006.02.057, 16762633.
34. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394. 10.1158/0008-5472.CAN-06-0800, 16885332.
35. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, Ørntoft TF, Andersen CL, Dobbelstein M. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008, 68:10094-10104. 10.1158/0008-5472.CAN-08-1569, 2836584, 19074875.
36. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009, 4:37-48. 10.1016/j.stem.2008.11.006, 2839936, 19128791.
37. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815. 10.1038/sj.onc.1204252, 11313928.
38. Sansam CL, Shepard JL, Lai K, Ianari A, Danielian PS, Amsterdam A, Hopkins N, Lees JA. DTL/CDT2 is essential for both CDT1 regulation and the early G2/M checkpoint. Genes Dev 2006, 20:3117-3129. 10.1101/gad.1482106, 1635147, 17085480.
39. Banks D, Wu M, Higa LA, Gavrilova N, Quan J, Ye T, Kobayashi R, Sun H, Zhang H. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 2006, 5:1719-1729.
40. Higa LA, Banks D, Wu M, Kobayashi R, Sun H, Zhang H. L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 2006, 5:1675-1680.
41. Ju J, Kane SE, Lenz HJ, Danenberg KD, Chu E, Danenberg PV. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. Clin Cancer Res 1998, 4:2229-2236.
42. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999, 5:643-654.
43. Peters GJ, Smitskamp-Wilms E, Smid K, Pinedo HM, Jansen G. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res 1999, 59:5529-5535.
44. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991, 25:306-318. 10.1016/0190-9622(91)70199-C, 1918470.
45. Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 1976, 36:4418-4424.
46. Yamauchi A, Ichimiya T, Inoue K, Taguchi Y, Matsunaga N, Koyanagi S, Fukagawa T, Aramaki H, Higuchi S, Ohdo S. Cell-cycle-dependent pharmacology of methotrexate in HL-60. J Pharmacol Sci 2005, 99:335-341. 10.1254/jphs.FP0050761, 16327215.
47. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y, Furukawa Y. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro. Jpn J Cancer Res 2001, 92:74-82.
48. Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008, 14:6751-6760. 10.1158/1078-0432.CCR-08-1034, 18980968.
49. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
50. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S. CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120. 2391278, 18497886.
51. Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics 2009, 6:19-29.
52. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006, 2:113-121. 2134920,2134920, 18079988.